COBALT: Coversin Global Study: An Open-Label, Safety and Efficacy Trial in PNH Patients

Trial Profile

COBALT: Coversin Global Study: An Open-Label, Safety and Efficacy Trial in PNH Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Coversin (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COBALT
  • Sponsors Akari Therapeutics
  • Most Recent Events

    • 25 Jun 2017 Interim results(n=5) assessing efficacy and safety, presented at the 22nd Congress of the European Haematology Association.
    • 23 Jun 2017 According to an Akari Therapeutics media release, poster containing data for the four patients were presented at the 22nd Congress of the European Hematology Association (EHA)
    • 30 May 2017 According to an Akari Therapeutics media release, the company has announced that the previously reported interim analysis of this trial, as stated in the media release dated 24 April 2017 (the Release), was inaccurate with respect to one of five patients for whom information was provided in the Release. The Company expects to release additional results with respect to the four continuing patients in this trial in approximately four weeks.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top